Cerenis names Richard Pasternak chair
This article was originally published in Scrip
Cerenis Therapeutics, a biopharmaceutical company developing an engineered human apoA-I-containing pre-β HDL mimetic for the treatment of cardiovascular disease, has appointed Dr Richard C Pasternak chair of the board of directors. He succeeds Dr Jean-Pierre Garnier, who is stepping down from the company for personal reasons. Dr Pasternak has spent the last 35 years as an academic and biopharmaceutical clinician-scientist, with a long-standing research interest in vascular disease, lipid disorders and atherosclerosis, as well as prevention and patterns of practice and disease management. He has been a non-executive director on Cerenis' board since November 2011.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.